| 发明名称 | Glucagon analogues | ||
| 摘要 | The invention provides materials and methods for the treatment of obesity and excess weight, diabetes, and other associated metabolic disorders. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon. | ||
| 申请公布号 | US9180169(B2) | 申请公布日期 | 2015.11.10 |
| 申请号 | US201314029529 | 申请日期 | 2013.09.17 |
| 申请人 | Zealand Pharma A/S | 发明人 | Tolborg Jakob Lind;Fosgerau Keld;Nørregaard Pia;Just Rasmus;Riber Ditte;Hamprecht Dieter Wolfgang;Augustin Robert;Thomas Leo;Rist Wolfgang |
| 分类号 | A61K45/06;A61K38/26;C07K14/605 | 主分类号 | A61K45/06 |
| 代理机构 | Clark & Elbing LLP | 代理人 | Clark & Elbing LLP ;Biecker-Brady Kristina |
| 主权项 | 1. A compound having the formula: R1—X—Z—R2 wherein R1 is H, C1-4 alkyl, acetyl, formyl, benzoyl or trifluoroacetyl; R2 is OH or NH2; X is a peptide which has the formula: HSQGTFTSDYSKYLDS-K(Hexadecanoyl-isoGlu)-AAEDFVEWLLRA (SEQ ID NO:7), and Z is absent or is a sequence of 1-20 amino acid units independently selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Cys, Glu, Lys, Arg, Dbu, Dpr and Orn,or a pharmaceutically acceptable salt thereof. | ||
| 地址 | Glostrup DK | ||